Deletion of specific immune-modulatory genes from modified vaccinia virus ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques

Journal of Virology

Volumn 86, Issue 23, 2012, Pages 12605-12615

  Garber, David A ^a,b,d   O'Mara, Leigh A ^a   Gangadhara, Sailaja ^a   McQuoid, Monica ^a   Zhang, Xiugen ^a   Zheng, Rui ^a   Gill, Kiran ^a   Verma, Meena ^a   Yu, Tianwei ^a   Johnson, Brent ^a   Li, Bing ^a   Derdeyn, Cynthia A ^a,b   Ibegbu, Chris ^a   Altman, John D ^a,b   Hunter, Eric ^a,b   Feinberg, Mark B ^a,b,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA RECEPTOR; UNCLASSIFIED DRUG; URACIL DNA GLYCOSIDASE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GENE DELETION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINATION; VACCINIA VIRUS; VIRUS GENE; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE DELETION; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACACA MULATTA; RECEPTORS, CHEMOKINE; RECEPTORS, INTERLEUKIN-1; T-LYMPHOCYTES; VIRAL VACCINES;

MACACA MULATTA; ORTHOPOXVIRUS; POXVIRIDAE; PRIMATES; VACCINIA VIRUS ANKARA;

EID: 84869232606     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00246-12     Document Type: Article

References (87)

1. Alcami A, Khanna A, Paul NL, Smith GL. 1999. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80(Pt 4):949-959.
2. Alcami A, Smith GL. 1996. A mechanism for the inhibition of fever by a virus. Proc. Natl. Acad. Sci. U. S. A. 93:11029-11034.
3. Alcami A, Smith GL. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-167.
4. Alcami A, Symons JA, Smith GL. 2000. The vaccinia virus soluble alpha/ beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74:11230-11239.
5. Amanna IJ, Carlson NE, Slifka MK. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357:1903-1915.
6. Antoine G, Scheiflinger F, Dorner F, Falkner FG. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
7. Bahar MW, et al. 2008. Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog. 4:e5. doi:10.1371/ journal.ppat.0040005.
8. Barouch DH, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93.
9. Bejon P, et al. 2007. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP among children in Kenya. PLoS One 2:e707. doi:10.1371/ journal.pone.0000707.
10. Beveridge NE, et al. 2007. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specificCD4 memory T lymphocyte populations. Eur. J. Immunol. 37:3089-3100.
11. Blanchard TJ, Alcami A, Andrea P, Smith GL. 1998. Modified vacciniavirus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79:1159-1167.
12. Bonsignori M, et al. 2009. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 183:2708-2717.
13. Bowie A, et al. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 97:10162-10167.
14. Buchbinder SP, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
15. Carroll MW, Moss B. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198-211.
16. Casimiro DR, et al. 2004. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replicationdefective adenovirus and poxvirus vaccine vectors. J. Virol. 78:11434-11438.
17. Cebere I, et al. 2006. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417-425.
18. Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL. 2006. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J. Gen. Virol. 87:29-38.
19. Corey L, McElrath MJ, Kublin JG. 2009. Post-step modifications for research on HIV vaccines. AIDS 23:3-8.
20. Corona Gutierrez CM, et al. 2004. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther. 15:421-431.
21. Cottingham MG, et al. 2008. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 3:e1638. doi:10.1371/journal.pone.0001638.
22. Currier JR, et al. 2010. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5:e13983. doi:10.1371/ journal.pone.0013983.
23. Dangoor A, et al. 2010. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol. Immunother. 59:863-873.
24. Davies DH, et al. 2008. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J. Virol. 82:652-663.
25. Derdeyn CA, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022.
26. Dorrell L, et al. 2007. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA. HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25:3277-3283.
27. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79(Pt 2):347-352.
28. Dunachie SJ, et al. 2006. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74:5933-5942.
29. Garber DA, Feinberg MB. 2006. Probing the possibilities for T-cell-based AIDS vaccines. Curr. Opin. HIV AIDS 1:314-322.
30. Garber DA, et al. 2009. Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 4:e5445. doi:10.1371/journal.pone.0005445.
31. Garber DA, Silvestri G, Feinberg MB. 2004. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4:397-413.
32. Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M. 2010. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate(MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5:e12395. doi:10.1371/journal.pone.0012395.
33. Gilbert PB, et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191:666-677.
34. Goepfert PA, et al. 2011. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 203:610-619.
35. Guimaraes-Walker A, et al. 2008. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 26:6671-6677.
36. Haase AT. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-223.
37. Hansen SG, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-299.
38. Harari A, et al. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205:63-77.
39. Hawkridge T, et al. 2008. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198:544-552.
40. Haynes BF, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
41. Haynes BF, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
42. Hill AV, et al. 2010. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6:78-83.
43. Hirao LA, et al. 2010. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol. Ther. 18:1568-1576.
44. Hirsch VM, et al. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
45. Holzer GW, Falkner FG. 1997. Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. J. Virol. 71:4997-5002.
46. Jaoko W, et al. 2008. Safety and immunogenicity of recombinant lowdosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26:2788-2795.
47. Keefer MC, et al. 2011. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948-1958.
48. Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. 2010. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum. Vaccin. 6:784-791.
49. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. 2010. HIV vaccines: lessons learned and the way forward. Curr. Opin. HIV AIDS 5:428-434.
50. Letvin NL, et al. 2006. Preserved CD4 central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-1533.
51. Liu J, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
52. Mayr A, Hochstein-Mintzel V, Stickl H. 1975. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA. Infection [3:6] -14.
53. McElrath MJ, et al. 2008. HIV-1 vaccine-induced immunity in the testof-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905.
54. McShane H, et al. 2005. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb.) 85:47-52.
55. McShane H, et al. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244.
56. Meyer H, Sutter G, Mayr A. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virusMVAand their influence on virulence. J. Gen. Virol. 72:1031-1038.
57. Mooij P, et al. 2009. Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens. J. Virol. 83:5881-5889.
58. Mooij P, et al. 2008. Differential CD4 versus CD8 T-cell responseselicited by different poxvirus-based human immunodeficiency virus type [1] vaccine candidates provide comparable efficacies in primates. J. Virol. 82:2975-2988.
59. Moorthy VS, et al. 2004. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189:2213-2219.
60. Moorthy VS, et al. 2004. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1:e33. doi:10.1371/journal.pmed.0010033.
61. Mwau M, et al. 2004. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNAand recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919.
62. Ng A, Tscharke DC, Reading PC, Smith GL. 2001. The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J. Gen. Virol. 82:2095-2105.
63. Nicol MP, Grobler LA. 2010. MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr. Opin. Mol. Ther. 12:124-134.
64. Parrino J, et al. 2007. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25:1513-1525.
65. Pathan AA, et al. 2007. Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One 2:e1052. doi:10.1371/ journal.pone.0001052.
66. Peters BS, et al. 2007. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25:2120-2127.
67. Pitisuttithum P, et al. 2006. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
68. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
69. Sandstrom E, et al. 2008. Broad immunogenicity of a multigene, multiclade HIV-1DNAvaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490.
70. Shiver JW, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
71. Slifka MK, Ahmed R. 1998. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10: 252-258.
72. Smith CL, et al. 2005. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113:259-266.
73. Smith CL, et al. 2005. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol. 175: 8431-8437.
74. Smith GL, Symons JA, Alcami A. 1999. Immune modulation by proteins secreted from cells infected by vaccinia virus. Arch. Virol. Suppl. 15:111-129.
75. Smith VP, Bryant NA, Alcami A. 2000. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J. Gen. Virol. 81:1223-1230.
76. Spriggs MK, et al. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71:145-152.
77. Stack J, et al. 2005. Vaccinia virus protein A46R targets multiple Tolllike-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201:1007-1018.
78. Staib C, Kisling S, Erfle V, Sutter G. 2005. Inactivation of the viral interleukin 1beta receptor improves CD8 T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J. Gen. Virol. 86:1997-2006.
79. Stittelaar KJ, et al. 2001. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700-3709.
80. Symons JA, et al. 2002. The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J. Gen. Virol. 83:2833-2844.
81. Symons JA, Tscharke DC, Price N, Smith GL. 2002. A study of thevaccinia virus interferon-gamma receptor and its contribution to virus virulence. J. Gen. Virol. 83:1953-1964.
82. UNAIDS. 2009. AIDS epidemic update. UNAIDS, Geneva, Switzerland.
83. Vasan S, et al. 2010. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B=/C candidate vaccine. PLoS One 5:e8816. doi:10.1371/journal.pone.0008816.
84. Walker LM, Burton DR. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22:358-366.
85. Wilson NA, et al. 2006. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80:5875-5885.
86. Wong S, Siliciano R. 2007. Biology of early infection and impact on vaccine design, p 17-22. In Koff W, Kahn P, Gust I (ed), AIDS vaccine development: challenges and opportunities. Caister Academic Press, Wymondham, United Kingdom.
87. Wrammert J, Ahmed R. 2008. Maintenance of serological memory. Biol. Chem. 389:537-539.